Prime Medicine, Inc. Common Stock (PRME) - Net Assets
Based on the latest financial reports, Prime Medicine, Inc. Common Stock (PRME) has net assets worth $76.70 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($294.73 Million) and total liabilities ($218.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Prime Medicine, Inc. Common Stock's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $76.70 Million |
| % of Total Assets | 26.02% |
| Annual Growth Rate | 110.47% |
| 5-Year Change | -49.55% |
| 10-Year Change | N/A |
| Growth Volatility | 848.95 |
Prime Medicine, Inc. Common Stock - Net Assets Trend (2019–2025)
This chart illustrates how Prime Medicine, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See PRME days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Prime Medicine, Inc. Common Stock (2019–2025)
The table below shows the annual net assets of Prime Medicine, Inc. Common Stock from 2019 to 2025. For live valuation and market cap data, see Prime Medicine, Inc. Common Stock market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $120.87 Million | -21.08% |
| 2024-12-31 | $153.15 Million | +15.09% |
| 2023-12-31 | $133.07 Million | -57.92% |
| 2022-12-31 | $316.27 Million | +32.02% |
| 2021-12-31 | $239.56 Million | +615.66% |
| 2020-12-31 | $33.47 Million | +2309.94% |
| 2019-12-31 | $1.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prime Medicine, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 88575500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $82.00K | 0.07% |
| Other Components | $1.01 Billion | 834.91% |
| Total Equity | $120.87 Million | 100.00% |
Prime Medicine, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Prime Medicine, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hainan RuiZe New Building Material Co Ltd
SHE:002596
|
$570.95 Million |
|
Yoantion Industrial Inc.Ltd.
SHE:301053
|
$570.97 Million |
|
Everspin Technologies Inc
NASDAQ:MRAM
|
$571.18 Million |
|
Pareto Bank ASA
OL:PARB
|
$571.24 Million |
|
Zhong Fu Tong Co Ltd
SHE:300560
|
$570.51 Million |
|
Vinte Viviendas Integrales S.A.B. de C.V
MX:VINTE
|
$570.49 Million |
|
Echoiq Ltd
AU:EIQ
|
$570.48 Million |
|
Network18 Media & Investments Limited
NSE:NETWORK18
|
$570.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prime Medicine, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 153,149,000 to 120,868,000, a change of -32,281,000 (-21.1%).
- Net loss of 201,142,000 reduced equity.
- New share issuances of 138,390,000 increased equity.
- Other comprehensive income increased equity by 81,000.
- Other factors increased equity by 30,390,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-201.14 Million | -166.41% |
| Share Issuances | $138.39 Million | +114.5% |
| Other Comprehensive Income | $81.00K | +0.07% |
| Other Changes | $30.39 Million | +25.14% |
| Total Change | $- | -21.08% |
Book Value vs Market Value Analysis
This analysis compares Prime Medicine, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.89x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 217.79x to 3.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.01 | $3.16 | x |
| 2020-12-31 | $0.35 | $3.16 | x |
| 2021-12-31 | $2.50 | $3.16 | x |
| 2022-12-31 | $3.25 | $3.16 | x |
| 2023-12-31 | $1.46 | $3.16 | x |
| 2024-12-31 | $1.29 | $3.16 | x |
| 2025-12-31 | $0.81 | $3.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prime Medicine, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -166.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4342.44%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 2.84x
- Recent ROE (-166.41%) is below the historical average (-106.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -182.07% | 0.00% | 0.00x | 6.26x | $-2.67 Million |
| 2020 | -10.19% | -65.45% | 0.10x | 1.64x | $-6.76 Million |
| 2021 | -69.03% | 0.00% | 0.00x | 1.26x | $-189.32 Million |
| 2022 | -38.52% | -2338.21% | 0.01x | 1.14x | $-153.45 Million |
| 2023 | -148.89% | 0.00% | 0.00x | 1.46x | $-211.44 Million |
| 2024 | -127.90% | -6566.61% | 0.01x | 1.94x | $-211.20 Million |
| 2025 | -166.41% | -4342.44% | 0.01x | 2.84x | $-213.23 Million |
Industry Comparison
This section compares Prime Medicine, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prime Medicine, Inc. Common Stock (PRME) | $76.70 Million | -182.07% | 2.84x | $570.75 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder ca… Read more